Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)Business Wire • 05/22/25
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?Zacks Investment Research • 05/20/25
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease DrugZacks Investment Research • 05/15/25
GSK splashes out $1.2bn up-front for liver treatment still in clinical trialsProactive Investors • 05/14/25
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)Business Wire • 05/14/25
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to knowCNBC • 05/12/25
Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'The Guardian • 05/12/25
GSK and Lifetime® launch original movie to raise awareness about the impact of meningitisBusiness Wire • 05/09/25
EU drugs regulator confirms suicidal thoughts as side effect of anti hair-loss drugReuters • 05/08/25
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loomCNBC • 04/30/25
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff ReassuranceZacks Investment Research • 04/30/25
Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | GSK Leads Cervarix Market Amid Global Vaccination EffortsGlobeNewsWire • 04/30/25
Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug SalesBenzinga • 04/30/25